



FOR IMMEDIATE RELEASE

## **Horizon Technology Finance Management Leads \$20 million Senior Venture Loan Facility to Calypso Medical Technologies, Inc., a Leader in Improving Radiation Treatment**

Farmington, CT – September 2008: Horizon Technology Finance Management and its affiliate, Compass Horizon Funding Company LLC (collectively, “Horizon”), a leading venture lender supporting venture capital-backed firms in the information technology and life science industries, announced today that it closed a \$20 million Senior Venture Loan Facility for Calypso Medical Technologies, Inc. (“Calypso”), a medical device company. The facility is a revolving credit loan which allows for the flexible use of funds over the next 30 months. Calypso’s 4D Localization System, referred to as GPS for the Body<sup>®</sup>, provides a revolutionary radiation targeting technology for improving the treatment of cancer patients. CIT’s HealthCare Life Science Group also participated in the transaction.

Gerald A. Michaud, President of Horizon, said, “We are very excited to provide Calypso with this venture loan financing facility. We expect Calypso’s real time tumor location technology to be a leading and revolutionary improvement in the treatment of prostate cancer and other cancerous tumor targets.” Michaud added, “Since 2004, Horizon has provided over \$700 million in loans to information technology and life science companies backed by top tier venture capital investors and we are pleased to add Calypso to our growing portfolio.”

Eric Meier, Chief Executive Officer of Calypso, stated, “Horizon’s revolving venture loan facility provided us with just the right creative financing we need at this stage of our growth. Horizon’s loan will provide us with the critical growth capital we need to meet customer demand for the Calypso System over the next few years. We are pleased to add Horizon Technology Finance Management and CIT’s HealthCare Life Science Group to our top tier group of investors and finance partners.” Calypso is backed by a seasoned group of medical device venture capital investors including Frazier Healthcare, Bay City Capital, Versant Ventures and others.

### **About Horizon:**

Horizon Technology Finance Management is a privately-held independent venture debt finance company that provides senior and subordinated venture debt financing solutions to venture capital-backed technology and life science companies through its affiliated investment finance company Compass Horizon Funding Company LLC. The Horizon team has provided over \$2 billion in financing to more than 750 venture capital-backed technology and life science companies over a span of 20 years. Horizon provides a compelling alternative to the restrictive structures offered by banks and corporate finance companies. Horizon’s team has over 150 years of collective venture and commercial lending experience and uses its extensive knowledge, expertise and industry relationships to provide custom venture debt products and financing solutions for its customers. Horizon has offices in Farmington, CT and the San Francisco, CA area. For more information, please visit [www.horizontechfinance.com](http://www.horizontechfinance.com).

Companies interested in learning more about financing opportunities should contact:

Gerald A. Michaud, President  
Horizon Technology Finance Management  
[jerry@horizontechfinance.com](mailto:jerry@horizontechfinance.com)  
Or call 860-676-8659

**About Calypso:**

Calypso Medical Technologies, Inc. (“Calypso”) is a Seattle, WA-based privately held emerging medical device company. With over 185 employees across the US and holding over 100 patents, Calypso is dedicated to shaping the future of cancer care by becoming the world’s choice for targeting radiation therapy. The Company’s proprietary tumor tracking system, known as the GPS for the Body® system, is designed for body-wide cancers commonly treated with radiation therapy, including prostate, breast, lung, liver, head, neck and other cancers. It is currently FDA 510(k) cleared for use in the prostate in the prostatic bed in post-prostatectomy patients.

**About CIT Healthcare Group:**

CIT (NYSE: CIT) is a global commercial finance company that provides financial products and advisory services to more than one million customers in over 50 countries across 30 industries. A leader in middle market financing, CIT has more than \$70 billion in managed assets and provides financial solutions for more than half of the Fortune 1000. A member of the S&P 500 and Fortune 500, it maintains leading positions in asset-based, cash flow and Small Business Administration lending, equipment leasing, vendor financing and factoring. The CIT brand platform, Capital Redefined, articulates its value proposition of providing its customers with the relationship, intellectual and financial capital to yield infinite possibilities. Founded in 1908, CIT is celebrating its Centennial throughout 2008. [www.cit.com](http://www.cit.com).